The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Investors worry patients won’t make that price leap and that Hims, which has built its business on affordable healthcare, ...

Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

BofA keeps an Underperform rating on Hims & Hers with a $22 price target after the company indicated it is adding a branded version of Eli ...